AU2021268223C1 - Compound having KDM5 inhibitory activity and pharmaceutical use thereof - Google Patents

Compound having KDM5 inhibitory activity and pharmaceutical use thereof

Info

Publication number
AU2021268223C1
AU2021268223C1 AU2021268223A AU2021268223A AU2021268223C1 AU 2021268223 C1 AU2021268223 C1 AU 2021268223C1 AU 2021268223 A AU2021268223 A AU 2021268223A AU 2021268223 A AU2021268223 A AU 2021268223A AU 2021268223 C1 AU2021268223 C1 AU 2021268223C1
Authority
AU
Australia
Prior art keywords
general formula
alkyl
compound
azabicyclo
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021268223A
Other languages
English (en)
Other versions
AU2021268223B2 (en
AU2021268223A1 (en
Inventor
Masaki Asada
Daigo Inoyama
Akito KAKUUCHI
Kyle KONZE
Goran KRILOV
Anatoly RUVINSKY
Mats Svensson
Hidenori Takahashi
Shuhei UMEMURA
Yan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of AU2021268223A1 publication Critical patent/AU2021268223A1/en
Application granted granted Critical
Publication of AU2021268223B2 publication Critical patent/AU2021268223B2/en
Publication of AU2021268223C1 publication Critical patent/AU2021268223C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021268223A 2020-05-07 2021-05-06 Compound having KDM5 inhibitory activity and pharmaceutical use thereof Active AU2021268223C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/088925 2020-05-07
CN2020088925 2020-05-07
PCT/CN2021/091843 WO2021223699A1 (en) 2020-05-07 2021-05-06 3-azabicyclo(3.1.0)hexane derivatives having kdm5 inhibitory activity and use thereof

Publications (3)

Publication Number Publication Date
AU2021268223A1 AU2021268223A1 (en) 2022-12-08
AU2021268223B2 AU2021268223B2 (en) 2025-10-09
AU2021268223C1 true AU2021268223C1 (en) 2026-07-09

Family

ID=76159223

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021268223A Active AU2021268223C1 (en) 2020-05-07 2021-05-06 Compound having KDM5 inhibitory activity and pharmaceutical use thereof

Country Status (13)

Country Link
US (3) US11691968B2 (cg-RX-API-DMAC7.html)
EP (2) EP4471027A1 (cg-RX-API-DMAC7.html)
JP (3) JP7643466B2 (cg-RX-API-DMAC7.html)
KR (2) KR102937044B1 (cg-RX-API-DMAC7.html)
CN (1) CN115461338B (cg-RX-API-DMAC7.html)
AU (1) AU2021268223C1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022005A2 (cg-RX-API-DMAC7.html)
CA (1) CA3181604A1 (cg-RX-API-DMAC7.html)
ES (1) ES3037418T3 (cg-RX-API-DMAC7.html)
IL (1) IL297900B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022013692A (cg-RX-API-DMAC7.html)
TW (1) TWI895412B (cg-RX-API-DMAC7.html)
WO (1) WO2021223699A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999183A4 (en) * 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
AU2021268223C1 (en) 2020-05-07 2026-07-09 Ono Pharmaceutical Co., Ltd. Compound having KDM5 inhibitory activity and pharmaceutical use thereof
JP2023070165A (ja) * 2021-11-05 2023-05-18 小野薬品工業株式会社 アザビシクロ環化合物の結晶
JP7743829B2 (ja) * 2021-11-05 2025-09-25 小野薬品工業株式会社 Kdm5阻害作用を有する化合物を含有する医薬組成物
TW202612686A (zh) * 2024-05-17 2026-04-01 日商小野藥品工業股份有限公司 失智症之行動及心理症狀之預防、進展抑制及/或治療劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057924A1 (en) * 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0311859D0 (en) 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
EP1765379A4 (en) 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
WO2009047161A1 (en) 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
CN108341819B (zh) 2017-01-22 2021-06-15 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂及其用途
EP3999183A4 (en) 2019-07-17 2023-11-15 Ono Pharmaceutical Co., Ltd. COMPOUNDS HAVING KDM5 INHIBITANT ACTION AND THEIR PHARMACEUTICAL USES
AU2021268223C1 (en) 2020-05-07 2026-07-09 Ono Pharmaceutical Co., Ltd. Compound having KDM5 inhibitory activity and pharmaceutical use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057924A1 (en) * 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors

Also Published As

Publication number Publication date
BR112022022005A2 (pt) 2022-12-13
CN115461338B (zh) 2024-02-20
US12269817B2 (en) 2025-04-08
JP7643466B2 (ja) 2025-03-11
US20230109293A1 (en) 2023-04-06
US20250214984A1 (en) 2025-07-03
CN115461338A (zh) 2022-12-09
JP7643632B2 (ja) 2025-03-11
MX2022013692A (es) 2022-11-30
KR20260046494A (ko) 2026-04-07
JP2025081677A (ja) 2025-05-27
EP4471027A1 (en) 2024-12-04
JP2024177345A (ja) 2024-12-19
KR20230007352A (ko) 2023-01-12
EP4146645B1 (en) 2025-06-25
IL297900B2 (en) 2026-04-01
US20230271952A1 (en) 2023-08-31
EP4146645A1 (en) 2023-03-15
ES3037418T3 (en) 2025-10-01
KR102937044B1 (ko) 2026-03-09
IL297900A (en) 2023-01-01
NZ793960A (en) 2025-12-19
JP2023524547A (ja) 2023-06-12
AU2021268223B2 (en) 2025-10-09
WO2021223699A1 (en) 2021-11-11
CA3181604A1 (en) 2021-11-11
TW202200571A (zh) 2022-01-01
AU2021268223A1 (en) 2022-12-08
US11691968B2 (en) 2023-07-04
IL297900B1 (en) 2025-12-01
TWI895412B (zh) 2025-09-01

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JAN 2026

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JAN 2026

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 FEB 2026